Peter Radice, MD

Articles by Peter Radice, MD

Rationale for Trials Studying Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer

ByMohammad Jahanzeb, MD,Cynthia Frankel, RN,Mohammed Elkersh, MD,Alan Koletsky, MD,Peter Radice, MD,Charles L. Vogel, MD, FACP

October 1st 1997

Breast cancer is second only to lung cancer as a leading cause of cancer mortality in women. In women with metastatic, hence, essentially incurable disease, we strive to find effective chemotherapeutic regimens that offer a

Latest Updated Articles

Rationale for Trials Studying Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer
October 1st 1997

Trending on CancerNetwork

124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)